男性乳腺癌药物治疗研究进展  

Progress in the pharmacotherapy of male breast cancer

作　　者：崔芳[1] 陆苏[1] 刘红[1] 

机构地区：[1]天津医科大学肿瘤医院乳腺二科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室乳腺癌防治教育部重点实验室,天津市300060

出　　处：《中国肿瘤临床》2015年第21期1071-1074,共4页Chinese Journal of Clinical Oncology

摘　　要：男性乳腺癌(male breast cancer,MBC)是一种少见的恶性疾病,有关治疗及预后的大型临床研究较少,目前对其多依据女性乳腺癌(female breast cancer,FBC)治疗。尽管男性乳腺癌与女性乳腺癌有较多相似之处,但二者仍存在较大差异,主要表现在对激素的依赖性及对激素治疗的敏感性不同。男性乳腺癌内分泌治疗的用药选择及用药时机仍存在较多争议,对常规内分泌药物耐药的男性乳腺癌患者的其他安全有效的治疗措施有待进一步研究。本文将就近年来男性乳腺癌药物治疗方面的研究进展进行综述,为临床治疗提供参考。Male breast cancer （MBC） is an uncommon malignant disease, with few large-scale clinical studies on its treatment and prognosis. To date, MBC management is based on the guidelines for female breast cancer （FBC）. Although MBC and FBC share many similarities, a few differences still exist between them, specifically in their hormonal dependence and sensitivity to endocrine ther- apy. Therefore, the drug selection and medication time remain controversial in the endocrine therapy of MBC. Furthermore, other safe and effective measures for MBC patients who are resistant to traditional endocrine therapy deserve further study. This review summariz- es recent major advances in MBC drug treatments, which intends to provide a reference for clinical treatment.

关 键 词：乳腺肿瘤 男性 雌激素受体 人类表皮生长因子受体-2 他莫昔 芬芳香化酶抑制剂 

分 类 号：R737.9[医药卫生—肿瘤]